Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-301-8233
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
Weill Cornell MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2015 - 2025
NY State Medical License 2012 - 2017- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Start of enrollment: 2019 Feb 21
Publications & Presentations
PubMed
- 641 citationsUpdated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.Ann-Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux
Journal of Hepatology. 2022-04-01 - 3477 citationsAtezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaRichard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux
The New England Journal of Medicine. 2020-05-13 - 1594 citationsPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
The Lancet. Oncology. 2018-07-01
Journal Articles
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerOlatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology
Authored Content
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
Press Mentions
Independence Valued over Survival for Neuroendocrine Tumor PatientsDecember 30th, 2022- Longer Survival Not Top Priority for Some Patients with CancerDecember 28th, 2022
- First Patient Dosed with Experimental Cancer-Killing Virus in New TrialJune 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
